Shots:
GSK to acquire 100% of the outstanding shares of Affinivax with a total consideration of ~$3.3B incl. $2.1B up front & $0.6B upon achievement of milestones. The transaction is expected to close in Q3’22
The acquisition bolsters GSK’s vaccines R&D pipeline, provides access to Affinivax’s MAPS technology for pneumococcal diseases & expands its footprint in the Boston area. The acquisition will establish a strong portfolio of innovative vaccines & therapy, providing access to a 24-valent pneumococcal vaccine candidate currently in P-II trial
In the P-I/II trials, AFX3772 was well tolerated & showed good immune responses. The vaccine’s use in paediatrics will initiate in 2022 & the P-III is expected to initiate shortly
Ref: GSK | Image: GSK
